Short Interest in Nyxoah SA (NASDAQ:NYXH) Decreases By 48.5%

Nyxoah SA (NASDAQ:NYXH) saw a large decline in short interest in August. As of August 31st, there was short interest totaling 244,313 shares, a decline of 48.5% from the August 15th total of 474,703 shares. Based on an average trading volume of 108,052 shares, the days-to-cover ratio is currently 2.3 days. Currently, 0.8% of the company’s stock are short sold.

Institutional Trading of Nyxoah

Institutional investors have recently added to or reduced their stakes in the business. Readystate Asset Management LP acquired a new position in shares of Nyxoah during the 2nd quarter valued at about $351,000. Integrated Wealth Concepts LLC bought a new position in shares of Nyxoah in the 2nd quarter valued at approximately $169,000. Finally, IFP Advisors Inc lifted its holdings in Nyxoah by 35.6% in the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock worth $200,000 after purchasing an additional 31,061 shares during the last quarter.

Nyxoah Stock Up 0.6%

NASDAQ NYXH traded up $0.01 on Wednesday, reaching $1.55. The stock had a trading volume of 152,930 shares, compared to its average volume of 547,378. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44. Nyxoah has a 1 year low of $1.26 and a 1 year high of $6.87. The business has a 50 day moving average price of $1.55 and a 200 day moving average price of $2.33. The company has a market capitalization of $60.08 million, a price-to-earnings ratio of -0.62 and a beta of 1.63.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20). The firm had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. On average, analysts forecast that Nyxoah will post -1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on NYXH shares. Oppenheimer set a $4.00 price target on shares of Nyxoah in a research report on Thursday, August 6th. Stifel Nicolaus lowered their price objective on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Wednesday, June 17th. Wall Street Zen lowered shares of Nyxoah from a “hold” rating to a “sell” rating in a research note on Sunday, August 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nyxoah in a research report on Wednesday, August 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Nyxoah in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nyxoah currently has an average rating of “Hold” and an average price target of $4.26.

About Nyxoah

Nyxoah SA is a medical technology company focused on developing treatments for obstructive sleep apnea (OSA), a sleep-related breathing disorder caused by repeated airway obstruction during sleep. The company is headquartered in Mont-Saint-Guibert, Belgium, and trades on Nasdaq under the symbol NYXH.

Nyxoah’s principal product is the Genio system, an implantable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to activate the nerves controlling the tongue and upper-airway muscles, helping maintain an open airway during sleep.